Opere BioNTech BNTX

Vender
 Comprar

BioNTech gráfico en tiempo real

5m 15m 30m 1h 4h 1d 1w

Fundamentales del instrumento

Weekly Search
Weekly
Daily
Fecha Cerrar Cambio Cambio del % Apertura Alto Bajo

Últimas noticias

2025 Mar 29, 16:00

Adelanto semanal: Llegan las nóminas no agrícolas de EE. UU.: Qué deberías esperar

2025 Mar 22, 16:00

Adelanto semanal: Inversores, atentos a la inflación y PCE para el movimiento de la Fed

Forex Índices
2025 Mar 15, 16:00

Adelanto semanal: BoJ, Fed, SNB y BoE: ¿Cómo afectarán al mercado?

2025 Mar 04, 16:00

Adelanto semanal: Inflación de EE. UU. y tasas del BoC serán el foco de atención

2025 Mar 01, 16:00

Adelanto semanal: El mercado espera la decisión de tasas del BCE y los datos laborales de EE. UU.

2025 Feb 22, 16:00

Adelanto semanal: Inflación en Australia e índice de precios PCE subyacente de EE. UU.

2025 Feb 13, 16:00

Adelanto semanal: ¿Realizarán el Banco de la Reserva de Australia y el Banco de la Reserva de Nueva Zelanda movimientos de tipos inesperados?

2025 Feb 08, 16:00

Adelanto semanal: Los inversores estarán pendientes de la inflación en EE. UU.

Información

Spread

1.1295

Spread (%)

1.1972 %

Apalancamiento

1:10

Interés a un día (Compra)

-0.0597 %

Interés a un día (Venta)

-0.0292 %

Divisa

USD

Horarios de los mercados

Markets closed

Lunes

13:31 - 19:59

Martes

13:31-19:59

Miércoles

13:31-19:59

Jueves

13:31-19:59

Viernes

13:31-19:59

Análisis y estadísticas

Apertura

---

Cierre anterior

---

Máximo/mínimo de 52 semanas

--- – ---

Capitalización de mercado

22785247232

Acciones en circulación

239971008

Fecha de ganancias (próxima)

0000-00-00

Rentabilidad por div.

2022-06-17

Fecha exdividendo

2022-06-02

Tasa de dividendo anual anticipado

0

Rendimiento de dividendo anual anticipado

0

GPA

-2.97

Conoce más sobre este instrumento

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Instrumentos relacionados

Activo
Vender
Comprar
Cambio del %

Opere ahora

Opere ahora

Opere ahora

Opere ahora
view_all_instruments
Trustpilot